Video - Results from #50

Imaging: Prostate Cancer VL

The Future of Advanced Prostate Cancer Imaging Presentation - Stefano Fanti Details Stefano Fanti presents his point of view on the future of prostate cancer imaging at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He shares his thoughts on the use of conventional imaging such as CT and bone scan and why they should be regarded as obsolete, and why novel imaging such as PET PSMA and MRI should be incorporated into practice immediately. Dr. Fanti believes that th...
Imaging Bone (Flare) Responses in Advanced Prostate Cancer Presentation - Anwar Padhani Details Anwar Padhani presents at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 on imaging and flare responses when assessing patients with metastatic castration-resistant prostate cancer (mCRPC). In his presentation, Dr. Padhani notes that bone scans/CT scans lead to poor confidence for knowing the true clinical states and assessing therapy benefits for bone disease in advanced prostate...
Integrating Advanced Molecular Imaging into Clinical Practice - Michael Morris Details Michael Morris joins Alicia Morgans to discuss advanced molecular imaging, and how we can take the data we have and integrate it into our clinical practices. They discuss recent results of the Prostate Cancer Working Group as well as the patient where advanced molecular imaging is most useful. Finally, Dr. Morris provides his recommendation to clinicians gaining access to these scans and how to us...
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman Details Charles Ryan and Michael Hofman share in a discussion on the use of new imaging techniques in prostate cancer, the sensitivity of imaging and the use of theranostics PSMA targeted therapies for metastatic castrate-resistant prostate cancer. Michael Hofman details the quick advance of PSMA imaging in Australia. He highlights PSMA tracers including Gallium-68 and PSMA-Based [18F]DCFPyL PET/CT and th...
Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer by Michael Hofman Details Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically. Biographies: Michael Hofman, MBBS (Hon...
Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer - Phillip Koo Details In this 5 for 5 Hot Topics, Phillip Koo, MD. presents the clinical background of Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer, the first FDA-approved F18 PET Imaging Agent indicated in for use in patients with suspected recurrent prostate cancer. Dr. Koo discusses its use for men with suspected prostate cancer recurrence based on elevated PSA levels following...